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Abstract
Objective To compare trends in breast cancer mortality within three
pairs of neighbouring European countries in relation to implementation
of screening.
Design Retrospective trend analysis.
Setting Three country pairs (Northern Ireland (United Kingdom) v
Republic of Ireland, the Netherlands v Belgium and Flanders (Belgian
region south of the Netherlands), and Sweden v Norway).
Data sources WHO mortality database on cause of death and data
sources on mammography screening, cancer treatment, and risk factors
for breast cancer mortality.
Main outcome measures Changes in breast cancer mortality calculated
from linear regressions of log transformed, age adjusted death rates.
Joinpoint analysis was used to identify the year when trends in mortality
for all ages began to change.
Results From 1989 to 2006, deaths from breast cancer decreased by
29% in Northern Ireland and by 26% in the Republic of Ireland; by 25%
in the Netherlands and by 20% in Belgium and 25% in Flanders; and by
16% in Sweden and by 24% in Norway. The time trend and year of
downward inflexion were similar between Northern Ireland and the
Republic of Ireland and between the Netherlands and Flanders. In
Sweden, mortality rates have steadily decreased since 1972, with no
downward inflexion until 2006. Countries of each pair had similar
healthcare services and prevalence of risk factors for breast cancer
mortality but differing implementation of mammography screening, with
a gap of about 10-15 years.
Conclusions The contrast between the time differences in
implementation of mammography screening and the similarity in
reductions in mortality between the country pairs suggest that screening
did not play a direct part in the reductions in breast cancer mortality.
Introduction
Deaths from breast cancer are decreasing in North America,
Australia, and most Nordic and western European countries.
1-3
After more than 20 years of intensive mammography screening
in some of these countries, however, it is still difficult to
determinehowmuchoftheobservedreductioninmortalitycan
beattributedtoearlierdetectionofbreastcancerortoimproved
management.
4 5 This difficulty stems from the limited ability of
most observational and modelling studies to disentangle the
effectsofearlydetection,treatment,andefficiencyofhealthcare
systems on mortality.
6
Deathsfromcervicalcancerhavedecreasedsubstantiallyinthe
same countries.
3 7 Reductions in cervical cancer mortality in
Nordic countries from 1965 to 1980 were related to nationwide
screening programmes from the 1960s (Iceland, Finland). In
countrieswherescreeningprogrammesweredelayed(Norway),
the reduction in mortality became apparent many years later.
Finland implemented a nationwide cytology screening
programmeinthe1960s,andfrom1970to1980mortalityfrom
cervical cancer decreased by 50%. In Norway, a nationwide
programme was implemented 15 years later, and from 1970 to
1980 mortality from cervical cancer decreased by only 8%.
Access to surgery and radiotherapy was comparable between
theNordiccountries,andthecleardifferencesinmortalitytrends
could be attributed to time differences in the implementation
of screening. These data remain the most compelling evidence
that cytology screening reduces mortality from this cancer.
8 9
Studies of cervical cancer mortality at the population level
suggest an approach that may help clarify the effectiveness of
mammography screening. A review of randomised trials on
mammography screening carried out by an international expert
group suggested that in areas with screening attendance of at
least 70%, a reduction in breast cancer mortality by about 25%
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Research
RESEARCHmay be expected in women screened between 50 and 69 years
of age and by about 19% in women screened between 40 and
49 years.
6 Bearing in mind the experience with cytology
screening for cervical cancer, the reduction in mortality in
countries that implemented mammography screening early
would be expected to appear before any reduction in similar
countries with later implementation of screening.
We assessed trends in breast cancer mortality in pairs of
neighbouring European countries where mammography
screening had been implemented many years apart. We also
examined potential factors that could mask the influence of
screening on trends in mortality observed within each pair.
Methods
WeselectedpairsofEuropeancountriesbasedonthreecriteria:
the countries had to be neighbours; the countries had to have
similar population structure, socioeconomic circumstances,
quality of healthcare services, and access to treatment; and
nationwidemammographyscreeninginonecountryhadtohave
existed since around 1990, with implementation some years
later in the matched country. From information on
mammography screening activities we summarised the
population structure (for example, life expectancy, proportions
of women in screening ages), socioeconomic circumstances,
cultural environment, educational level, quality of healthcare
services, and access to treatment for the 27 member states of
the European Union, plus Norway, Switzerland, and Iceland.
From these data, three pairs of countries met the selection
criteria: Sweden and Norway, the Netherlands and Belgium,
and Northern Ireland (United Kingdom) and the Republic of
Ireland. For Belgium, we also sought data specific to the
Flandersregion,theareadirectlyneighbouringtheNetherlands
where 60% of the Belgian population lives. We chose to take a
closer look at Flanders as its medical culture, cultural
background, socioeconomic status, language, and access to
treatments are similar to those in the Netherlands. Belgium
comprises two other regions, Brussels (10% of the population)
and Wallonia (30% of the population), where French is spoken
and where cultural patterns are more like those of France.
Moreover, the organisation of mammography screening in
Flanders was similar to the organisation in the Netherlands,
whereas this was not the case for Brussels and Wallonia.
Breast screening activities
Using information from published peer reviewed articles or
reports we summarised mammography screening activities in
eachcountryforthe1990sand2000-5.
10-22Wedefinedorganised
screening as a population based programme to which women
of defined ages were regularly invited to screening
mammography. Non-organised screening was defined as
screeninglefttothediscretionofthewomenordoctors,without
any centrally organised invitation or follow-up systems. In
non-organised screening, women aged 40-49 seemed to be
screened at least as frequently as women aged 50-69. For
Sweden and Norway we used data on year of first invitation to
screening.ForBelgium,theNetherlands,NorthernIreland,and
the Republic of Ireland we extracted data on attendance for
screening in the past two years (three years in the United
Kingdom) by women aged 50-64 or 50-69 (depending on
eligibility in the respective organised programmes), whatever
the screening modality.
Breast cancer mortality data
We extracted data on deaths from breast cancer registered in
the World Health Organization mortality database as of May
2010 for the six countries for 1980 to 2006.
23 In addition to
WHO data, we obtained information on mortality statistics for
Belgium. Specific mortality rates for Belgium were recorded
until 1997, after which they became available for Flanders and
Brussels until 2006, whereas for Wallonia mortality data were
available only for 2004. For Wallonia we estimated mortality
rates from 1998 to 2003, and for 2005 and 2006 by linear
interpolation calculated with data for 2004 for all the countries
andusingdatafrom1989and2004forFlandersandtheBrussels
regionasaproxyfortimetrendsinBelgium.Wethenestimated
a national mortality rate for Belgium using regional rates
weighted by population size.
Statistical analysis
We used the age distribution of the European standard
population to obtain European standardised age adjusted
mortality rates. The analysis of trends in rates was based on
knowledge that in 1989 a national screening programme was
implemented in Sweden and that programmes were starting in
NorthernIrelandandtheNetherlands.Wefittedcountryspecific
Poisson regression models from 1989 until 2006 using annual
numbers of breast cancer deaths and corresponding numbers of
women by five year age groups. For the Poisson regression
model specific to Flanders, we obtained annual population data
by five year age groups from the Statistics Belgium for 1989 to
2004. For 1980-9, we used five year age groups reported by the
populationcensusin1981
24andagespecificdemographicgroups
available in 1989 for interpolating population numbers from
1982 to 1988. From the slope of each country we derived the
annual percentage change in breast cancer mortality and the
overall percentage change from 1989 to 2006 (1989 to 2004 for
Belgium). We carried out these analyses for women of all ages
and for women aged less than 50, 40-49, 50-69, 70-79, and 70
years and older. Analysis by age group was not possible for
Flandersbecauseagespecificandregionspecificmortalitydata
were not available before 1997.
We analysed temporal trends in mortality among women of all
ages using joinpoint regression, version 3.4.2 of the software
from the surveillance research programme of the US National
Cancer Institute.
25 Joinpoint regression consists of fitting a
straight line on a logarithmic scale to the trends in annual age
standardised rates. While fitting the straight line, the joinpoint
programme identifies (through permutation analysis) years
during which statistically significant inflexions in trend occur.
The user may decide a priori whether the programme should be
allowed to identify one or several possible years during which
significant inflexions occur. If only one joinpoint is allowed,
then the programme will identify the year with the strongest
change in trend. If two joinpoints are allowed, the programme
willreturnthetwoyearswiththehigheststatisticalsignificance.
Joinpointregressionwasdoneondatafrom1980to2006(1980
to 2004 for Belgium). We selected the minimum significant
number of joinpoints identified from the permutation test and
alsoextractedresultsforthemodelwithoneadditionaljoinpoint.
Thisenabledustoidentifywhetheranadditionalnon-significant
downward trend could also be noticed.
Confounders
We examined several factors associated with breast cancer
mortality, as differences in their prevalence could contribute to
differences in mortality trends between country pairs.
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RESEARCHOf all lifestyle and reproductive factors, obesity (as measured
by body mass index) at the time of cancer diagnosis seems to
be the strongest factor associated with a poor prognosis.
26 We
used the prevalence of obesity in women aged 18 and older
around 2000 that was available for the six countries,
27 28 as well
as data on obesity trends in the United Kingdom and the
Republic of Ireland.
29 The association of reproductive factors
with breast cancer incidence is well established and the risk
increases with decreasing fertility and increasing age at first
birth. But the association with breast cancer mortality is less
clear.
26 However, we extracted figures on fertility (average
numberofchildrenbornaliveperwoman)andmeanageatfirst
birth from Eurostat
27 and from other sources for Flanders
30 31
and Northern Ireland.
32 We used the available figures for the
earlier year quoted for both countries of a pair.
For the management of breast cancer, we extracted data from
the 2008 Karolinska Institute report on expenditures and
adoptionofanticancerdrugs.
33Asindicatorsofcurativeactivities
against cancer, we used the sales of anticancer drugs (annual
per capita average) from 1990 to 2005, the uptake of new
anticancer drugs in general (as sales per three month periods)
after their introduction in the country, and the uptake of
trastuzumab (as sales per three month period) after its
introduction in the country. For the last two indicators we
compared countries with an ad hoc European average based on
13countries(E13:Austria,Denmark,Finland,France,Germany,
Republic of Ireland, Italy, the Netherlands, Norway, Spain,
Sweden, Switzerland, and the United Kingdom). We found no
data on tamoxifen use that would allow comparison between
countries of each pair. We also used per capita expenditures on
health (adjusted for purchasing power parities) extracted from
the WHO statistical information system database.
34
Results
Sweden and Norway
The national organised mammography screening programme
in Sweden was implemented from 1986 onwards after a pilot
study and the results of clinical trials carried out in the country
in the 1970s and 1980s (table 1).
10 In 1990 about 90% of
Swedish women had received a first invitation. Nationwide
coverage was attained in 1997 (fig 1). All women aged 50-69
are invited, but in most counties (60-70%) women aged 40-49
are also invited.
11 In half the counties women aged 70-74 are
invited. Attendance for screening in Sweden has been
consistently among the highest recorded in any country.
12
Non-organised screening is uncommon.
TheNorwegianorganisedmammographyscreeningprogramme
was initiated in 1996 as a pilot project in four counties, which
include 40% of Norway’s population (Akershus, Hordaland,
Oslo, Rogaland).
13 14 Since then organised screening has been
gradually implemented, with all women aged 50-69 invited
every two years. By 2005 the programme had reached
nationwide coverage. For the implementation of nationwide
screeningthetimedifferencebetweenSwedenandNorwaywas
about 12 years. Non-organised screening was uncommon after
implementation of the nationwide programme.
From1989to2006,breastcancermortalitydecreasedby16.0%
in Sweden and by 24.1% in Norway (table 2 and fig 1).
The Netherlands and Belgium
In the Netherlands, a national organised mammography
screening programme was initiated in 1989 (table 1). After
gradual implementation, the programme reached full coverage
in 1997.
15 16 Women aged 50-69 are invited to mammography
every two years, and since 1998 women aged 70-74 are also
invited.Figure2showsthatparticipationinscreeninggradually
increased from 1989 to 1996, and after 1997 it has remained
constant at around 70-79%. Non-organised screening is
uncommon.
In Belgium, breast screening was left to the discretion of the
womenanddoctorsuntil2001,afterwhichanationalscreening
programme was established. Population surveys before 1999
suggested that less than 30% of women in the 50-69 year age
group had undergone mammography during the past two years
(for screening or diagnostic purposes).
17 Around 2000, about
30% of women aged 50-69 had undergone screening or
diagnostic mammography in the past two years.
18 19 By around
2005thisproportionhadincreasedtoabout59%(fig2).Atthat
time two thirds of screening examinations were done as part of
the organised programme in Flanders, and for less than one
sixth in Brussels and Wallonia. Participation in screening
(organised and non-organised) in Flanders was low until about
2002-3, and by 2004-6 it was still below the coverage in the
Netherlands in 1997 (fig 2).
In the Netherlands the overall reduction in breast cancer
mortalityfrom1989to2006wasslightlygreaterthaninBelgium
(25.0% v 19.9%) but did not differ noticeably from Flanders
(25.0% v 24.6%; table 2 and fig 2).
Northern Ireland (United Kingdom) and
Republic of Ireland
The United Kingdom organised mammography screening
programmewasintroducedinNorthernIrelandatthebeginning
of the 1990s (table 1).
20 It includes women aged 50-64, who are
invited to screening every three years. In 2003-4 the age range
was extended to women up to age 70. Unlike the rest of the
United Kingdom, Northern Ireland used two view
mammography from the start. Attendance steadily increased
during the 1990s and has remained stable, at around 70-75%,
since 1995.
21 Non-organised screening is uncommon.
Anationalorganisedmammographyscreeningprogrammewas
introduced in the Republic of Ireland in 2000, firstly in the
eastern part of the country and then over several years achieved
nationwidecoverage.Womenaged50-69areinvitedeverytwo
years. Before that breast screening was left to the discretion of
thewomenanddoctorsandcoveragewaslow.In2002national
coveragewasabout30%.Ithasgraduallyincreasedandin2008
was 76%.
22
From1989to2006,breastcancermortalitydecreasedby29.6%
in Northern Ireland and by 26.7% in the Republic of Ireland
(table 2 and fig 3).
Further comparisons
Table 2 summarises mortality trends for all women and by age
group.InSweden,mortalitytrendshadsteadilydecreasedsince
1972
2 and screening implementation did not lead to a new
inflexion in trends after 1972. In Northern Ireland and the
Netherlands,mortalitystartedtodecreaseshortlyafterscreening
was introduced. In Belgium, Norway, and the Republic of
Ireland, mortality started to decrease years before most women
in the target age groups attended screening. In these three
countries, when a second joinpoint was forced, the second year
of inflexion in mortality trends always occurred before most
eligible women participated in the screening.
Overall, the greatest reduction in breast cancer mortality has
occurred among younger women, aged 40 to 49 (table 2). This
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RESEARCHwas also the case for Northern Ireland and Norway, where
mammographyscreeningbeforetheageof50israre.Inwomen
aged 70-79, the reduction in breast cancer mortality varied
substantially by country, with strong reductions in the
Netherlands, Norway, and the Republic of Ireland.
Confounders
Reproductive factors did not differ substantially within each
pair (table 3). The prevalence of obese women was similar
withineachcountrypair,exceptthatobesitywasmoreprevalent
inNorthernIrelandthanintheRepublicofIreland.(Since1998,
obesity in the Republic of Ireland has increased much faster
than in Northern Ireland (data not shown),
29 a situation that
could have contributed to an increase in breast cancer mortality
in the Republic of Ireland.)
The summary economic indicators suggest that average
healthcare expenditures were higher in the Republic of Ireland
and in Norway compared with Northern Ireland and Sweden,
whereas the expenditures in Belgium and the Netherlands
appearedtobesimilar.Uptakeofrecentanticancerdrugsseemed
to be slower in Northern Ireland than in the other countries. No
data related to uptake of anticancer drugs were available for the
Republic of Ireland.
Access to cancer treatment did not differ between the
Netherlands and Belgium or between Sweden and Norway. In
2001, information on treatment suggested small differences
between Northern Ireland and the Republic of Ireland.
35
Compared with Northern Ireland, the Republic of Ireland had
higher rates of chemotherapy (49.8% v 38.4%), slightly lower
rates of radiotherapy (63.4% v 68.6%), and lower use of
tamoxifen as adjuvant therapy (47.7 v 75.6%).
35
Discussion
Trends in breast cancer mortality rates varied little between
countries where women had been screened by mammography
foraconsiderabletimecomparedwiththosewherewomenwere
largely unscreened during that same period. This is in sharp
contrast with the temporal difference of 10 to 15 years in
implementation of mammography screening and suggests that
screeninghasnotplayedadirectpartinthereductionsofbreast
cancer mortality.
Strengths and limitations of the study
Our study is based on population level data, but its value goes
beyond a simple ecological study because the three countries
that implemented screening relatively late were otherwise
closely matched to the countries where nationwide screening
programmes started before 1991. By comparing changes in
disease incidence or mortality between geographical areas that
haveimplementedacertaininterventionwithotherwisesimilar
areas without the intervention, the effectiveness of the
intervention may be assessed. For instance, this method was
recently used to assess the public health impact of the ban on
smokinginpublicareas,usingthesubsequentincidenceofacute
myocardial infarction as outcome.
36 Also, studies of mortality
trends for cervical cancer in the Nordic countries used a similar
approach and are considered to be the best evidence for the
effectiveness of screening for cervical cancer.
8 9
Studies at a population level are none the less limited by their
inability to control confounding. It is therefore reasonable to
question which factors could have caused the near absence of
a difference in breast cancer mortality within the country pairs.
We found no differences in risk factors for breast cancer or in
access to treatment within each pair that could have
counterbalanced the influence of screening associated with the
decline in mortality. An as yet unknown confounding factor
couldobscuretherelationbetweenscreeningandmortality,but
it is unlikely that this would have affected all three pairs
simultaneously.
Factors possibly explaining findings
We also examined factors that could mask the interpretation of
the data. Firstly, differences in the quality of registration of
causes of death in country pairs is unlikely, mainly because the
registration of deaths from breast cancer may be more reliable
than for many other cancers.
37 38 Secondly, the six countries
have a longstanding tradition of recording causes of death.
Thirdly, WHO judged that the quality of cause of death data
within each pair of countries was comparable: high quality in
NorthernIrelandandtheRepublicofIrelandandmediumquality
in the four other countries.
39 Fourthly, we included information
on non-organised (opportunistic) screening in Belgium and the
Republic of Ireland using screening attendance statistics (table
1). In the four other countries, opportunistic screening is
uncommon.
11
Comparison with other studies
It may be questioned whether the observation period was long
enough for reliable comparisons to be made. The Malmö
randomised trial, which is usually considered as
methodologically robust, showed reductions in mortality eight
years after the start of screening.
40-42 At the population level,
however, longer follow-up is probably needed because
implementation of screening in the population is likely to take
moretime,andinourstudytheobservationperiodwas18years.
In the Netherlands, a 20 year mortality follow-up after
introducing mammography screening in the city of Nijmegen
in1975,showedthatbreastcancermortalitydidnotdeclineany
earlier than in the city of Arnhem or in the Netherlands as a
whole.
43Similartoourstudy,theinvestigatorscouldnotexplain
why the reduction did not start earlier in Nijmegen.
Mammography screening aims to detect cancer before it is
clinically apparent and before it has developed to an advanced
stage. As suggested by the randomised trials, widespread
organised screening would be expected to reduce the incidence
ofadvancedbreastcancerthatshouldbeobservableyearsbefore
reductionsinmortality.
6 44However,inanotherstudyweshowed
that contrary to expectations, the incidence of advanced breast
cancer in Northern Ireland and the Netherlands remained quite
stable (similar data are not available for Sweden) subsequent
to the implementation of screening.
45 Those results suggest that
follow-up longer than the 18 years of the present study is not
likely to change the differences in mortality trends between the
countries of each pair.
Year of start of the decline in mortality
The decline in mortality started between 1991 and 1996 in
Norway, Belgium, the Republic of Ireland, Northern Ireland,
and the Netherlands. In Sweden, the decline in breast cancer
mortalitythatstartedin1972hasremainedstableovertimeand
the reduction after 1989 was modest compared with other
European countries.
1 Mammography screening cannot explain
thesechangesintrendsbecausethereductioninmortalitystarted
too soon after screening was implemented in the Netherlands
andNorthernIreland,andbecausescreeningwasstilluncommon
in the four other countries. It seems more likely that the
downward inflexions observed from 1991 to 1996 stem from
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RESEARCHthe impact of adopting effective anticancer treatments, as
indicated by meta-analyses showing the positive influence of
such treatments on survival of patients with breast cancer.
46
Age at death
The greatest reductions in mortality were observed in women
younger than 50, independent of mammography screening in
that age group. The large mortality reduction in women aged
70andolderintheNetherlandshasbeeninterpretedasevidence
forscreeningeffectiveness.
47However,similarreductionswere
observed in Norway and the Republic of Ireland, and the
reductions in these countries cannot be attributed to screening.
It seems more plausible that the differences in reduction of
mortality among older women may be due to differences
between countries in the intensity of diagnostic efforts and
treatment.
48-50
Conclusions and policy implications
Thecontrastbetweenthetimingofbreastcancerscreeningbeing
implemented and the similarity in mortality reduction between
the country pairs do not suggest that a large proportion of the
mortality reduction after 1990 can be attributed to
mammography screening. Improvements in treatment and in
the efficiency of healthcare systems may be more plausible
explanations. Our study adds further population data to the
evidence of studies that have used various designs and found
that mammography screening by itself has little detectable
impact on mortality due to breast cancer.
14 44 51 52
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RESEARCHWhat is already known on this topic
Breast cancer mortality is decreasing in many countries but the association with mammography screening is difficult
to appraise
Cervical cancer mortality decreased earlier and more strongly in those Nordic countries that implemented nationwide
screening programmes compared with delayed screening
What this study adds
Breast cancer mortality in paired European countries with similar socioeconomic status and access to treatment were
comparable after 1989, despite a 10-15 year difference in implementation of mammography screening
The downward trends in mortality started before or shortly after the implementation of the screening programme
The greatest reductions were in women aged 40-49, regardless of the availability of screening in this age group;
reductions in women aged 70-79 were highly variable and did not correlate with the timing of screening in younger age
groups
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RESEARCHTables
Table 1| Indicators of mammography screening activities in country pairs
Country pairs Characteristics
Norway Sweden Belgium, Flanders Netherlands Republic of
Ireland
Northern
Ireland
Organised (1996
in 4/19 counties)
Organised
(1986)
Non-organised,
non-organised
Organised
(1989)
Non-organised Organised
(1990)
Predominant type of
screening activities, 1995-9
<30 >80 <30, <30 >70 <30 >70 % of women aged 50-69
screened, 1995-9*
Organised Organised Non-organised and
organised (2001),
organised (2001) and
non-organised
Organised Non-organised and
organised (2000)
Organised Predominant type of
screening activities, 2000-5*
>70 >80 50, 50 >75 50 >70 % of women screened,
2000-5*
50-69 (2) 40-74 (2)† 50-69 (2), 50-69 (2) 50-74 (2) 50-64 (2) 50-64 (3) Age groups invited to
organised screening
(interval in years), 2005
See text for data source references. Bracketed dates are year of start of programme unless stated otherwise.
*Screening of women less than 50 is common in non-organised screening.
†Interval every 18 months for age group 40-49.
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RESEARCHTable 2| Changes in breast cancer mortality between 1989 and 2006 in country pairs
Overall % change 1989-2006 by age group Joinpoint years when
forcing one additional
joinpoint
Joinpoint year for
start of decrease
after 1980*
Overall % change
1989-2006
Mean mortality rate
Country
70-79 50-69 40-49 2004-6 1987-9
−11.1 −36.7 −50.7 1994/1997 1991 −29.6 28.1 37.0 Northern Ireland
−18.7 −27.7 −45.2 1984/1989 1991 −26.7 30.5 40.3 Republic of Ireland
−26.7 −28.0 −25.2 1991/1999 1994 −25.0 30.1 39.0 Netherlands
−14.1 −21.4 −37.5 1986/1996 1996 −19.9 29.7 37.5 Belgium‡
NA NA NA 1982/1996 1996 −24.6 30.1 38.9 Flanders
−9.7 −16.0 −35.5 1992/2006 No joinpoint year† −16.0 22.0 25.6 Sweden
−22.8 −22.8 −33.5 1993/1995 1994 −24.1 21.5 27.4 Norway
NA=not available.
*Joinpoint year of statistical significant at P<0.05 (two sided).
†Last joinpoint year was 1972.
2
‡Until 2005.
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RESEARCHTable 3| Factors possibly associated with breast cancer mortality in country pairs
Drug uptake v E13 average Per capita expenditures
% women
with body
Mean age at first
birth (year) Fertility* (year) Country Trastuzumab Anticancerdrugs
Anticancer drug
sales (€),
<1995-2005
Health in 2005
(PPP international
US$)
mass index
≥30
Below Slow 12.5 2598 23.2 25.0 (1978) 2.7 (1978) Northern Ireland
NA NA NA 3125 10.6 25.5 (1980) 3.2 (1980) Republic of
Ireland
Below Average 17.9 3187 10.2 24.8 (1960)/26.6
(1985)
3.1 (1960)/2.4
(1971)
Netherlands
Average Average 19.1 3071 11.9 25.5 (1960)/25.5
(1985)
2.6 (1960)/2.2
(1971)
Belgium
NA NA NA NA NA NA (1960)/25.7
(1987)
NA (1960)/2.2
(1971)
Flanders
Average Average 19.4 3012 9.0 26.3 (1990) 2.2 (1968)/2.1
(1980)
Sweden
Below Average 15.5 4331 7.0 25.6 (1990) 2.9 (1968)/1.9
(1980)
Norway
€1.00 (£0.88; $1.41).
See methods section for data sources and list of E13 (European) countries. PPP=purchasing power parity; NA=not available.
*Mean number of children born alive per woman.
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RESEARCHFigures
Fig 1 Year of first invitation for mammography screening and age adjusted (European standardised rates) breast cancer
mortality in women of all ages in Sweden and Norway
Fig 2 Participation in mammography screening and age adjusted (European standardised rates) breast cancer mortality in
women of all ages in the Netherlands and Belgium
Fig 3 First year of organised screening programme and age adjusted (European standardised rates) breast cancer mortality
in Northern Ireland and Republic of Ireland
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